Extended Tumor Control After Dendritic Cell Vaccination With Low Dose Cyclophosphamide as Adjuvant Treatment in Patients With Malignant Pleural Mesothelioma.

CONCLUSIONS: Consolidation therapy with autologous tumor lysate-pulsed dendritic cell-based therapy and simultaneously reducing the tumor-induced immune suppression is well-tolerated, and shows signs of clinical activity in mesothelioma patients. Clinical trial registration available at www.clinicaltrials.gov, ID NCT01241682. PMID: 26652184 [PubMed - as supplied by publisher] (Source: American Journal of Respiratory and Critical Care Medicine)

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=158964942&cid=c_409_40_f&fid=36889&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F26652184%3Fdopt%3DAbstract